GlassScriptPhysician profile
Julia Fonte
NPI 1366565004
$20,612.00
in general payments reported to CMS, 2019-2025
33 companies · $2,971 in 2025
The $2,971 reported for 2025 was more than what 96% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,700 · 2022: $4,385 · 2023: $4,429 · 2024: $4,126 · 2025: $2,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,183.83 |
| Education | $342.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,786.34 | 2021-2025 | |
| Alkermes, INC. | $2,158.93 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $1,422.32 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceuticals, INC. | $1,337.10 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $1,287.13 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,248.64 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,233.47 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $852.94 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $686.92 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $681.29 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $662.90 | 2021-2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $645.99 | 2021-2024 | Spravato |
| Tris Pharma INC | $559.81 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $452.51 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $367.83 | 2023-2024 | Wegovy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $347.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.90 | 2021-2025 | Trintellix, Entyvio |
| Noven Therapeutics, LLC | $236.80 | 2023-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $222.92 | 2024-2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $222.70 | 2022 | |
| Eisai INC. | $146.39 | 2021 | |
| Lundbeck LLC | $145.86 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $111.57 | 2025 | Lumryz |
| Ironshore Pharmaceuticals INC. | $87.54 | 2022-2024 | Jornay Pm |
| Evofem Biosciences, INC. | $80.42 | 2021-2022 | |
| Almatica Pharma LLC | $78.79 | 2024-2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $66.80 | 2021 | |
| Lilly USA, LLC | $61.48 | 2023-2025 | Zepbound |
| Amgen INC. | $45.06 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.25 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $32.42 | 2021 | |
| Biogen, INC. | $25.59 | 2025 | Zurzuvae |
| Currax Pharmaceuticals LLC | $13.63 | 2023 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Fonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.